• ISSN: 2301-3567 (Print), 2972-3981 (Online)
    • Abbreviated Title: J. Econ. Bus. Manag.
    • Frequency: Quarterly
    • DOI: 10.18178/JOEBM
    • Editor-in-Chief: Prof. Eunjin Hwang
    • Executive Editor: Ms. Fiona Chu
    • Abstracting/ Indexing:  CNKI, Google Scholar, Electronic Journals Library, Crossref, Ulrich's Periodicals Directory, MESLibrary, etc.
    • E-mail: joebm.editor@gmail.com
JOEBM 2022 Vol.10(2): 110-114 ISSN: 2301-3567
DOI: 10.18178/joebm.2022.10.2.682

Based on Covid-19, Enterprise Valuation Analysis—A Case Study of Pfizer Inc.

Zhenpeng Liu

Abstract—Value investing, a common investment strategy introduced by Benjamin Graham, is used by lots of famous investors such as Warren Buffett, Seth Klarman, and Christopher Browne. Under the Covid-19 pandemic, this paper aims to determine if Pfizer, one of the world’s premier biopharmaceutical companies, is worth buying for value investors by investigating its fundamentals and valuation under this global crisis. Data for the past five years from Bloomberg was used to analyse its fundamental performance by comparing it to its peer group. Multiples valuation is used to determine whether it is undervalued or overvalued. The result shows that Pfizer is a quality stock that is undervalued.

Index Terms—Pfizer, covid-19, multiples valuation, financial analysis.

Zhenpeng Liu was with the University of Reading, Reading, RG6 6UR, United Kingdom (e-mail: Stewart924@outlook.com).


Cite:Zhenpeng Liu, "Based on Covid-19, Enterprise Valuation Analysis—A Case Study of Pfizer Inc. ," Journal of Economics, Business and Management vol. 10, no. 2, pp. 110-114, 2022.

Copyright © 2022 by the authors. This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Copyright © 2008-2024. Journal of Economics, Business and Management. All rights reserved.
E-mail: joebm.editor@gmail.com